Stockscreener 앱 받기
9.81
11.22%
-1.24
시간 외 거래:
10.04
0.23
+2.34%
전일 마감가:
$11.05
열려 있는:
$11.2
하루 거래량:
53,541
Relative Volume:
0.77
시가총액:
$691.81M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-8.83%
1개월 성능:
-17.01%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$9.76
$11.27
1주일 범위
$9.76
$11.80
52주 변동 폭
$7.90
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
9.81 | 779.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Yd Bio Ltd 주식(YDES)의 최신 뉴스
CMB.TECH Sells Two VLCCs, Realizing $98.2 Million Gain - Intellectia AI
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million By Investing.com - Investing.com Nigeria
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal By Investing.com - Investing.com South Africa
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal - Investing.com Canada
YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership - Nasdaq
YD Bio enters into binding LOI to acquire shares, assets of SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million - Investing.com
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy - The Manila Times
Cancer detection firm YD Bio targets $26.87M glioblastoma cell therapy deal - stocktitan.net
Diabetic Macular Edema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotech - Barchart.com
YD Bio Limited Announces Directorate Changes - marketscreener.com
YDES Stock Price, News & Analysis - Stock Titan
YD Bio Limited (YDES) board reshaped by majority holders’ written consent - Stock Titan
YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Research Tree
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal - Investing.com Australia
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal By Investing.com - Investing.com South Africa
How an AI cancer test in Taipei hospitals could help shape future drugs - Stock Titan
YD Bio Limited entered into a Memorandum of Understanding to acquire EG BioMed Co., Ltd. - MarketScreener
YD Bio advances cancer detection and eye disease platforms By Investing.com - Investing.com Australia
YD Bio LtdPlans to evaluate up to three acquisitions in 2026 - marketscreener.com
Yd Bio LtdPlans To Evaluate Up To Three Acquisitions In 2026 - TradingView — Track All Markets
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - Yahoo Finance
Micron and Lam Research among market cap stock movers on Tuesday By Investing.com - Investing.com India
YD Bio Limited Warrants (YDESW) Competitors - Meyka
YD Bio to establish California operations center for diagnostic development By Investing.com - Investing.com Australia
YD Bio to establish California operations center for diagnostic development - Investing.com India
YD Bio (Nasdaq: YDES) plans Calif. ops center for U.S. diagnostics - Stock Titan
Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound - simplywall.st
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN - Finviz
YD Bio expands cancer detection platform to pancreatic and colorectal cancers - Investing.com Australia
YD Bio expands cancer detection platform to pancreatic and colorectal cancers By Investing.com - Investing.com South Africa
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection - Yahoo Finance
YD Bio (Nasdaq: YDES) widens OkaiDx to 44 states, shows 93.8% early pancreatic sensitivity - Stock Titan
YD Bio Limited (YDESW) stock historical prices and data - Yahoo Finance UK
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday - Benzinga
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Tesla, Micron among market cap stock movers on Monday By Investing.com - Investing.com Australia
YD Bio stock rises after FDA clearance for eye care products - Investing.com Nigeria
YD Bio Stock Rises On Entry Into US Eye Care Segment - MSN
YD Bio receives FDA clearance for contact lenses and artificial tears - Investing.com India
Kyivstar Launches Starlink Direct to Cell Satellite Connectivity in Ukraine - The Manila Times
OMG Announces 28th Edition of Journal of Innovation - The Manila Times
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics - Yahoo Finance
YD Bio Limited (YDESW) Stock Historical Prices & Data - Yahoo! Finance Canada
YD Bio Limited (YDESW) company profile and facts - Yahoo Finance UK
[424B3] YD Bio Ltd Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
[6-K] YD Bio Ltd Current Report (Foreign Issuer) | YDES SEC FilingForm 6-K - Stock Titan
YD Bio Limited Announces Board and Committee Changes - MarketScreener
Yd Bio Ltd (YDES) 재무 분석
Yd Bio Ltd (YDES)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):